Monica M Mita
Overview
Explore the profile of Monica M Mita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, et al.
NPJ Precis Oncol
. 2023 Feb;
7(1):18.
PMID: 36797347
Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line treatment for HR+/HER2- metastatic breast cancer (MBC) patients. However, 30-40% of patients quickly develop disease progression. In...
2.
Mita M, Mita A
Br J Cancer
. 2020 Sep;
123(12):1713-1714.
PMID: 32989227
Over the last decade, bromodomain inhibitors have emerged as a promising class of anticancer drugs. However, the clinical progress of these agents has faced significant obstacles, which precluded their regulatory...
3.
Mita M, LoRusso P, Papadopoulos K, Gordon M, Mita A, Ferraldeschi R, et al.
Clin Cancer Res
. 2020 Jan;
26(12):2819-2826.
PMID: 31900279
Purpose: This first-in-human, phase I study evaluated ASTX660, an oral, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins in patients with advanced solid tumors or lymphoma. Patients And Methods: ASTX660...
4.
Sachdev E, Tabatabai R, Roy V, Rimel B, Mita M
Target Oncol
. 2019 Oct;
14(6):657-679.
PMID: 31625002
PARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class...
5.
Schram A, Gandhi L, Mita M, Damstrup L, Campana F, Hidalgo M, et al.
Br J Cancer
. 2018 Nov;
119(12):1471-1476.
PMID: 30425349
Background: This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib (MSC1936369B), a MEK1/2 inhibitor, in combination with voxtalisib (SAR245409), a pan-PI3K and...
6.
Mahalingam D, Goel S, Aparo S, Arora S, Noronha N, Tran H, et al.
Cancers (Basel)
. 2018 May;
10(6).
PMID: 29799479
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options...
7.
Carew J, Espitia C, Zhao W, Mita M, Mita A, Nawrocki S
Oncotarget
. 2017 Nov;
8(49):86769-86783.
PMID: 29156834
The tumor-selective viral replication capacity and pro-apoptotic effects of oncolytic reovirus have been reported to be dependent on the presence of an activated RAS pathway in several solid tumor types....
8.
Mita M, Mita A, Moseley J, Poon J, Small K, Jou Y, et al.
Br J Cancer
. 2017 Sep;
117(9):1258-1268.
PMID: 28859059
Background: Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability and pharmacokinetics of various dosing schedules of dinaciclib in...
9.
Gong J, Sachdev E, Robbins L, Lin E, Hendifar A, Mita M
Oncol Lett
. 2017 Apr;
13(3):1035-1040.
PMID: 28454210
Pancreatic cancer remains among the most lethal cancers, despite ongoing advances in treatment for all stages of the disease. Disease prevention represents another opportunity to improve patient outcome, with metabolic...
10.
Mita M, Nemunaitis J, Grilley-Olson J, El-Rayes B, Bekaii-Saab T, Harvey R, et al.
Target Oncol
. 2016 Jul;
11(6):807-814.
PMID: 27457707
Background: CEP-37250/KHK2804 is a recombinant, humanized, non-fucosylated, monoclonal antibody directed to sialic acid-containing glycoconjugates frequently found on certain tumor cell types. Objective: The objective was to determine the safety, tolerability,...